Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
INCB161734-101
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06179160 ↗
- Recruiting
- Incyte Corporation
- Focused
We haven't built an HCP commentary report on INCB161734-101 (INCB161734, cetuximab and 6 more) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INCB161734-101 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Solid Tumors
- Interventions
- INCB161734; Cetuximab; Retifanlimab; GEMNabP; mFOLFIRINOX; FOLFOX; FOLFIRI; INCA33890
- Arms
- Part 1a: Dose Escalation monotherapy · Experimental
- Part 1b: Dose Expansion monotherapy · Experimental
- Part 1c: Pharmacodynamic cohort · Experimental
- Part 2a: Dose Escalation combination · Experimental
- Part 2b: Dose Expansion combination · Experimental
- Part 1d: Food-Effect · Experimental
- Enrollment
- 710 (estimated)
- Primary outcomes
- Number of participants with Dose Limiting Toxicities (DLTs)
- Number of participants with Treatment-emergent Adverse Events (TEAEs)
- Number of participants with TEAEs leading to dose modification or discontinuation
- Sponsor
- Incyte Corporation
- Start
- Jan 4, 2024
- Primary completion
- Jan 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06179160 · updated Jul 22, 2026